ORPEF yields 14.06% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, ORPEF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ORPEF + PFE for your $10,000?
ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. The company operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.
Full ORPEF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.